This assumption is based on the clinical observation that, after response to platinum-based chemotherapy, patients with tumours classed as “HR-proficient” benefit less from PARPis compared to patients with HR-deficient or BRCA1/2 mutant tumours [14]. This evidence concerns the gene BRCA1 and neoplasm.